| Gene symbol | KRAS | Synonyms | C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras, K-Ras 2, KI-RAS, KRAS1, KRAS2, NS, NS3, OES, RALD, RASK2, c-Ki-ras, c-Ki-ras2 | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p12.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | KRAS proto-oncogene, GTPase | ||||
| GTO ID | GTC1711 |
| Trial ID | NCT03101839 |
| Disease | Lung Non-Small Cell Carcinoma |
| Altered gene | KRAS |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | AZD4785 |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase I, Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD4785 in Patients With Advanced Solid Tumours Where KRAS May Be an Important Driver of Tumour Survival |
| Year | 2017 |
| Country | United States|United Kingdom |
| Company sponsor | AstraZeneca |
| Other ID(s) | D8360C00001|REFMAL 484 |
| Vector information | |||
|
|||
| Cohort 1 | |||||
|
|||||